Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?

Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based on multiple guidelines. However, ethnic differences with respect to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:International journal of hematology Ročník 113; číslo 3; s. 330 - 336
Hlavní autoři: Iba, Toshiaki, Connors, Jean Marie, Spyropoulos, Alex C., Wada, Hideo, Levy, Jerrold H.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Singapore Springer Singapore 01.03.2021
Springer Nature B.V
Témata:
ISSN:0925-5710, 1865-3774, 1865-3774
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based on multiple guidelines. However, ethnic differences with respect to thrombogenicity have been reported and the incidence of thromboembolic events is considered to be lower in the Asian population. Despite the importance of thromboprophylaxis, bleeding is also a side effect that should be considered. We examine the data relating to potential ethnic differences in thrombosis and bleeding in COVID-19. Although sufficient data is not yet available, current evidence does not oppose routine anticoagulant use and thromboprophylaxis using a standard dose of LMWH for admitted patients regardless of ethnicity based on our review.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0925-5710
1865-3774
1865-3774
DOI:10.1007/s12185-021-03078-x